Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

Caitlin E. Cox

December 28, 2023

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Conference News EAS 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

Michael O'Riordan

May 24, 2022

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Shelley Wood

August 18, 2017

Advertisement

Year in Review: Top Prevention Stories of 2025

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

TCTMD’s Top 10 Most Popular Stories for December 2023

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

British Medical Groups Express Concern About Inclisiran Rollout

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content